Firefly Neuroscience, Inc
Firefly Neuroscience, Inc. develops and commercializes the BNA Platform, a brain-health assessment product that combines EEG-based measurement, software, and AI-driven analysis. The company targets neurologists and other healthcare professionals, while also pursuing collaborations with pharmaceutical companies supporting neuroscience drug development.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCore brain-health platform used to assess patients and support clinical decision-making.
BNA testing and usage-based services sold to clinics on a recurring basis.
Hardware sales and rentals tied to EEG and brain-activity measurement workflows.
Contracted research and clinical study work for pharmaceutical and neuroscience partners.
Products
Reported · share of revenue- Services71.3 %
- Products9.7 %
- Subscription and Circulation9.6 %
- Rentals6.5 %
- Other2.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company sells primarily to U.S. neurologists, healthcare professionals, and clinic-based medical practitioners who use the platform for patient assessment and management. It also targets pharmaceutical and neuroscience drug-development companies that need clinical-strategy support, biomarker insights, and study services. Adoption depends on proving clinical utility, workflow fit, and measurable patient-outcome benefits.
Buy BNA Platform licenses and per-use testing to support diagnosis and patient management.
Buy collaboration services for neuroscience drug development, clinical studies, and strategy support.
Use the platform in clinical settings to interpret brain function and guide therapy decisions.
Engage the company for projects that generate data, validate biomarkers, and support trials.
Strategy
The company’s near-term strategy is to commercialize the BNA Platform through targeted outreach, soft launches, and a direct sales effort into strategic clinic accounts. It is also building a second growth path through pharmaceutical collaborations that can generate project-based revenue and expand the clinical evidence base. The Evoke acquisition adds hardware/software capabilities and broadens the product set available for commercialization.
Clinic adoption is the main path to recurring product revenue and market validation.
Partner projects can fund development, generate data, and support biomarker discovery.
The acquisition adds hardware/software capabilities and expands the product portfolio.
Geography
Firefly is headquartered in the United States and its planned commercialization is centered on U.S. neurologists and healthcare professionals. The company’s current disclosures emphasize U.S. market rollout, while pharmaceutical collaborations may extend beyond clinic sales depending on partner needs. Geography matters mainly because regulatory, reimbursement, and adoption dynamics are tied to U.S. clinical practice.
Risks
Firefly remains a pre-commercial or early-commercial company, so execution risk around product adoption, sales conversion, and clinical validation is high. It also depends on external financing and may continue to burn cash while it scales the BNA Platform and integrates acquisitions. As a healthcare software and device-adjacent business, it faces regulatory, reimbursement, and competitive risks tied to proving clinical utility.
Revenue depends on convincing clinics and physicians to adopt a new brain-health workflow.
Exposure: Clinic sales and per-use fees
Management expects continued cash burn while investing in launch and integration.
Exposure: Liquidity and dilution risk
The value proposition depends on demonstrating better outcomes and practical utility.
Exposure: Physician acceptance and pharma partnerships
Evoke adds hardware/software operations that must be integrated into sales and cost structure.
Exposure: Product integration and COGS
Accounting
Judgemental itemsLicensing, per-use fees, equipment sales, rentals, and clinical studies may recognize revenue at different times.
Impact: Can affect quarterly comparability and reported growth
Management disclosed a change in derivative fair value affecting other income/expense.
Impact: Can create non-operating earnings volatility
The acquisition may create identifiable intangibles and potential goodwill that require ongoing assessment.
Impact: May affect amortization, impairment risk, and balance sheet presentation
Private placements and warrant exercises affect equity, dilution, and potentially derivative classification.
Impact: Can change share count and financing-related accounting
Similar listed companies
Publicly listed companies with a comparable business focus.
NeuroPace Inc
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
NeuroOne Medical Technologies Corporation
NMTC · Surgical & Medical Instruments & Apparatus
NeuroOne Medical Technologies develops and commercializes minimally invasive neurosurgical devices for diagnosing and treating brain and pain disorders.
ClearPoint Neuro, Inc.
CLPT · Surgical & Medical Instruments & Apparatus
Hyperfine, Inc.
HYPR · Electromedical & Electrotherapeutic Apparatus
Solana Co
HSDT · Finance Services
Solana Co is a U.S.-based public company organized around a Solana digital asset treasury strategy, with Solana (SOL) as its primary treasury reserve asset.
Enveric Biosciences, Inc.
ENVB · Pharmaceutical Preparations
Last updated: 28/04/2026